Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806518 | 1.00 | TLR2 (0.40) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL20467703 | 1.00 | TLR2 (0.40) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL15579833 | 0.96 | TLR2 (0.40) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL11922646 | 0.96 | HPGD (0.38) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL20467653 | 0.94 | GLP1R (0.46) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL25162403 | 0.93 | GLP1R (0.43) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL1895784 | 0.93 | GLP1R (0.43) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL20608161 | 0.93 | GLP1R (0.43) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL18379134 | 0.93 | GLP1R (0.43) | TLR2TLR1GLP1RHPGDHTT | |
| SCHEMBL2159690 | 0.93 | GLP1R (0.43) | TLR2TLR1GLP1RHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150633-B2 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2015-10-06 | — | — | US | disclosed |
| EP-2178912-B1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK AS (DK) | 2015-07-08 | — | — | EP | disclosed |
| EP-2708554-A1 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2014-03-19 | — | — | EP | disclosed |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | IAPP, INSR, IGF1R | TLR2 1756/4885TLR1 1709/4885GLP1R 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.